Feds fund $3.5M for Durham firm's yellow fever treatment
A Durham pharmaceutical company has received $3.5 million from a federal agency to support clinical trials for a drug to treat people with yellow fever.
For BioCryst Pharmaceuticals, the latest funds from the National Institute of Allergy and Infectious Diseases (NIAID) for galidesivir brings development contract funding to a total of $43 million.
BioCryst saw success during its Phase 1 trials; healthy patients tolerated the drug and found it to be safe. In animal studies, galidesivir showed…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Harrison Miller Source Type: news
More News: Allergy | Allergy & Immunology | American Health | Clinical Trials | Contracts | Funding | Health Management | Infectious Diseases | Study | Yellow Fever